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INTRODUCTION 
Liver, the largest gland in the body has many complex functions.  For 
the liver to perform its primary functions, high rates of blood flow and close 
contact between sinusoids and hepatocytes are essentials.                                                             
As a result of its complex vascular supply and high level of metabolic 
activity, the liver is uniquely vulnerable to a broad spectrum of circulatory 
disturbances. 
Heart failure, causes a number of pathophysiological effects which, 
alone or in combination result in liver cell damage.  As a consequence, liver 
function abnormalities are so common in heart failure. 
Liver dysfunction in heart failure is usually mild and asymptomatic and 
often detected incidentally on routine liver biochemical investigations. 
Present study was undertaken, mainly to emphasize the importance of 
early identification of liver serum biochemical markers in heart failure patients. 
Liver biochemical tests are found to be very useful in assessing the duration 
and severity of heart failure. Early and adequate treatment of the underlying 
cause of heart failure reverts liver function derangements to normal and 
prevents permanent liver damage. 
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AIMS OF THE STUDY 
1. To study the influence of  congestive heart failure on liver 
biochemical profiles. 
2. To assess the changes in liver biochemical tests in relation to the 
duration of  heart failure.  
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LITERATURE REVIEW 
 
ANATOMY AND PHYSIOLOGY 
Liver is richly supplied with blood and received fully 25% of the total 
cardiac output. Two thirds of the blood flow to the liver is supplied by the 
portal vein which is relatively lacking in oxygen. By contrast, the hepatic 
artery, which supplies only about one third of the total hepatic blood flow, 
carries oxygen–rich blood and accounts for more than 50%  of the oxygen 
delivered to the liver; it also provides the sole blood supply to the major bile 
ducts(1) . 
The functional unit of the liver is the hepatic acinus, which consists of a 
cluster of hepatocytes, grouped around hepatic arterioles and portal venules(1) . 
The centre of the acinus (periportal region) is known as zone 1, the periphery 
(perivenular region) as zone 3, the region in between as zone 2(2). 
Zone 1 receives highest levels of oxygen whereas zone 3 receives 
relatively hypoxic blood. The gradient is exaggerated in the setting of vascular 
collapse, when extraction of oxygen by zone 1 cells is increased to compensate 
for the reduction in hepatic blood flow and results in lower than normal oxygen 
tension in zone 3(3). Unlike portal venous flow, which lacks autoregulatory 
control, hepatic arterial flow is regulated closely to maintain a relatively 
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constant total hepatic blood flow. So, when portal blood flow diminishes, a rise 
in the local adenosine concentration results in compensatory arteriolar 
vasodilation(3) . 
LIVER PATHOGENESIS IN CONGESTIVE HEART FAILURE 
           Three factors are thought to be involved in the pathogenesis of liver 
function abnormalities: 
1. Decreased hepatic blood flow due to decreased cardiac output  which 
can result in hypoxia of the liver (4,5)  because of centrilobular damage, 
especially the zone 3(6). 
2. Passive congestion occurs in congestive cardiac failure which results in 
increased hepatic venous pressure and sinusoidal congestion. The 
resulting perisinusoidal odema results in decreased hepatic blood flow, 
atrophy and necrosis of centrilobular cells(3). 
Passive congestion alone is insufficient to cause significant hepatic 
necrosis; decreased hepatic blood flow is also necessary(8). So cardiac output is 
the principal determinant of hepatic ischemia(9) . Chronic passive congestion 
plays a major role in sensitizing the liver to hemodynamic and hypoxic  insults. 
3. Hypoxic hepatitis (shock liver ; ischaemic hepatitis) refers to diffuse 
hepatic injury following hypotension or acute hypoperfusion. Most 
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cases occur in the setting of congestive heart failure, although many 
other causes are also possible (10,11,12,13).     
           However, hypoxia per se does not produce centrilobular necrosis. 
Splanchnic ischaemia may result in absorption of endotoxin from the intestinal 
lumen, causing portal endotoxaemia which was superimposed on hypoxia to 
produce centrilobular necrosis (14). 
Liver dysfunction in congestive heart failure is usually mild and 
asymptomatic and often detected incidentally on routine liver biochemical 
testing. When symptomatic, it may present as mild jaundice. In patients with 
chronic, severe heart failure, jaundice may be so deep as to suggest biliary 
obstruction (15). When jaundice is accompanied by significant AT elevation in 
patients presenting with acute cardiac decompensation, the clinical picture may 
simulate that of acute viral hepatitis(16) . 
Congestive heart failure results in a broad range of liver biochemical 
abnormalities. Serum bilirubin is mildly elevated with a high unconjugated 
fraction(17). Multiple factors are thought to be contributary including 
hepatocellular dysfunction, hemolysis, pulmonary infarction, canalicular 
obstruction secondary to distended hepatic veins, medications and 
superimposed sepsis(8).  Jaundice of right sided heart failure seems to be 
clinically and pathophysiologically distinct from that of ischaemic hepatitis(8). 
Bilirubin level falls quickly with resolution of failure within three to seven days 
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(17). Even in the presence of deep jaundice, the serum alkaline phosphatase level 
is usually normal or only minimally elevated (18,19), a finding that helps 
distinguish cardiac from obstructive jaundice. It returns to normal in a week 
after treatment of failure.  
Serum AT levels are mildly elevated usually two to three times normal 
levels, in up to one third of patients with chronic heart failure (19,20). In patients 
with severe, acute heart failure, however, the AT levels may be extremely 
elevated,  simulating those of viral hepatitis(16), especially when the heart 
failure is complicated by hypotension(8) . However, high serum AT levels have 
been described in the setting of heart failure with minimal or no hemodynamic 
instability(9,21).  These probably reflect ischaemic injury secondary to decreased 
cardiac output because the degree of AT elevation correlates with the extent of 
zone 3 necrosis on liver biopsy specimens (22).  After the treatment of heart 
failure, AT levels return to normal within five to ten days(23).  
            Serum albumin levels are decreased in 30% to 50% of patients with 
cardiac decompensation. The incidence and degree of change, appear to be 
similar in acute and chronic failure(19,21) . The serum albumin level does not 
correlate with the degree of histological damage to the liver (19) . Causes of  low 
albumin probably include decreased hepatic synthesis, leakage from a 
congested intestine, and poor nutrition. With treatment, albumin level tends to 
rise over a period of one or more months(24) .  
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Prolonged prothrombin times are found in 80% to 90% of patients with 
acute and chronic heart failure (25,17,19) due to decreased hepatic synthesis of 
vitamin–k dependent clotting factors. It returns to normal in two to three weeks 
following treatment of the heart failure(24) . 
An uncommon complication of sustained chronic congestive cardiac 
failure is so–called cardiac sclerosis. The pattern of liver fibrosis is mostly 
centrilobular. The damage rarely fulfills the criteria for the diagnosis of 
cirrhosis, but the historically sanctified term cardiac cirrhosis cannot easily be 
dislodged (26). 
Cardiac sclerosis was the most common form of hepatic fibrosis, 
occurring in 48%  of cases. Cardiac fibrosis was quite frequent but frank 
cirrhosis was rarely found(27) . 
HISTOLOGICAL ASPECTS   
Antony Benivieni (1507) and Gionani Morgagni (1761) through their 
clinical works “De–Additis nonnilis ac minadis maeborum et Sanationum 
causis (about many usual and miraculous causes of diseases and their causes) 
and “De sedibus et causis Morborum per anatomen esidagitis” (about the sites 
and causes of diseases investigated by anatomy) can be considered to be 
pioneers in the study of pathology of liver. 
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“Acute central necrosis” of the liver was first described histologically by 
Kiernan et al, in 1833 and was initially associated only with severe congestive 
heart failure. Mallory et al, described the appearance of central congestion with 
focal necrosis in congestive heart failure.  
Garvin et al, in 1943, found 1.7 per cent of 407 patients were thought to 
have cirrhosis due to heart diseases(28). In an another study, Koletsky et al, in 
1944, found 35 (4.4 per cent) were considered to have cardiac cirrhosis at 
postmortem among 790 patients dying of heart diseases. 
Sherlock et al, 1951, described the clinical and biochemical features of 
zone 3 necrosis in heart failure. He found lack of correlation between right 
atrial pressure and the degree of zone 3 necrosis in patients with cardiac 
decompensation(8). This is followed by many studies which proved cardiac 
output is the major determinant of hepatic ischaenia which is the main 
contributing factor for liver function derangements(9). Sherlock found jaundice 
and hepatic synthetic function were no worse in patients with cardiac cirrhosis 
than in those with simple passive congestion(8).  
Bang et al, in 1959, have found serum liver enzymes elevation in 
congestive heart failure patients. Killip et al, in 1960, described massive 
elevations of serum AT levels secondary to cardiogenic shock(29) . 
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Richman et al, in 1961 described liver function test abnormalities in 175 
patients with congestive heart failure. They found acute heart failure is 
associated with more elevation of serum liver enzymes than chronic heart 
failure. They found even minor impairments of left ventricular function can 
lead to marked liver enzyme abnormalities(19) . West et al, in 1961, found 
elevation of AT levels is due to increase in systemic venous pressure, 
pulmonary capillary wedge pressure, cardiac index and other factors in 
congestive heart failure. They also found much higher levels of serum alkaline 
phosphatase are uncommon(18). In 1962, Logan et al, found very high serum 
liver enzyme levels, in congestive heart failure. They cautioned 
misinterpretation of these cases as viral or drug induced hepatitis(16). 
Refsum et al, in 1963, found right sided heart failure per se can not 
cause centrilobular necrosis. They also found no correlation between serum 
liver enzyme activities and the clinical signs of right heart failure. Yoshiko et 
al, in 1964, have stressed the importance of enzyme studies besides routine 
methods which reflect the obstruction and metabolic disturbances of liver cells 
in causes of congestive heart failure(30).   
In contrast to decrease in hepatic blood flow and passive congestion, 
arterial hypoxia does not appear to be an important cause of liver damage in 
congestive heart failure, as it is relatively uncommon in this condition(31).  
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Shorey et al (32) , 1969, and Whelan et al, 1969 found liver biochemical 
tests were normal in patients with hypoxia due to lung disease without heart 
failure. Whelan suggested that a degree of heart failure is necessary to produce 
abnormalities of liver function test. Heart failure may play a part in causing 
centrilobular liver all necrosis(33). Xarau et al, 1979, found the co existence of 
both factors was necessary. Dunn et al, 1973 described congestive hepatopathy 
and liver function abnormalities. In their study they have found 95% of patients 
had hepatomegaly, 20% had jaundice, 70% had elevated serum bilirubin levels 
and 12 to 33%  had elevated serum AT levels(17). 
Bynum et al, in 1979, described elevation of serum liver enzymes more 
than five times normal in the presence of centrilobular necrosis due to decrease 
in hepatic blood flow(22). The above studies, sherlock’s and many other studies 
suggested passive congestion alone is insufficient to cause significant 
centrilobular necrosis so as to rise serum liver enzymes. There must be 
significant decrease in cardiac output to produce these changes. 
Shock liver (Ischaemic hepatitis) is a severe hepatic derangement 
following a hypotensive or ischaenic insult(21).  The clinical picture varies from 
an isolated finding of very high AT levels after an episode of hypotension to 
fulminant hepatic failure after acute circulatory failure, often in the setting of 
established chronic heart failure(21). Jaundice, marked elevation of serum liver 
enzymes can all occur(29). It is the duration rather than the cause of the shock 
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that is important in the development of the syndrome. Shock of less than 24 
hours duration rarely causes central liver cell necrosis. Shock of more than 24 
hours does so invariably. The term “Ischaemic hepatitis” was introduced by 
Bynum et al, in 1979, captures the potential clinical resemblance of the entity 
to viral hepatitis. The histologic hallmark of  ischaemic hepathtis is zone 3 
necrosis.  The presence of chronic heart failure, a recent episode of acute 
circulatory failure, hepatomegaly, a rapid fall in serum AT levels after the 
initial rise and additional evidence of end-organ hypoperfusion especially acute 
tubular necrosis of the kidney with concomitant early rise in serum creatinine 
level favour a diagnosis of ischaemic hepatitis rather than viral or drug induced 
hepatitis(21).  
Serum albumin is low in about 30 to 50%  of patients with congestive 
heart failure. The incidence and the degree of change appear to be similar in 
acute and chronic failure. These changes were not marked. In 75% of those 
with reduced albumin, the values were between  2.5 to 2.9 g/dl (19). 
Sherlock in his series of 50 patients with heart failure, found eight 
patients with marked jaundice, with serum bilirubin levels ranging between 4.5 
to 22 mg/dl. Seven of these eight patients had mitral stenosis. He found a 
correlation of  the serum bilirubin level with the right atrial pressure, but not 
the cardiac output. Therefore, the jaundice of right sided heart failure seems to 
be clinically and pathophysiologically distinct from that associated with 
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ischaemic hepatits and results from congestion rather than diminished hepatic 
perfusion. 
Jaundice is found in less than 20% of patients with liver damage due to 
congestive heart failure, and depends on the severity of the heart failure, as 
evidenced by right atrial pressure, pulmonary wedge pressure, and cardiac 
index (20). However serum bilirubin is elevated in 20 to 80% patients with 
congestive heart failure. The elevated  serum bilirubin falls quickly with 
resolution of heart failure, usually becoming normal within three to seven days. 
Serum bilirubin level is usually less than 3 mg/dl and it rarely exceeds 5 
mg/dl(19,20). 
Extreme elevation of serum bilirubin and associated AT levels elevation 
would suggest extensive hepatic hecrosis(5). 
Gibson et al, in 1984, in their study of liver function tests in patients 
with likely fall in cardiac output have demonstrated marked rise in serum AT 
levels and short time course of enzyme elevation lasting 3 – 11 days. They 
concluded that ischaemic hepatitis was caused by poor hepatic perfusion 
associated with an acute fall in cardiac output(12). Kisloff et al(34), in 1976 and 
Nouel et al(21), 1980, demonstrated fulminant hepatic failure due to transient 
cirurlatory failure in patients with congestive heart failure. 
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Kaymakcalan et al, 1978, documented shock liver in congestive heart 
failure patients. They suggested it is a low cardiac output which causes 
decreased blood flow and parenchymal hypoxia, which is the main prerequisite 
for centrilobular necrosis. Shock is an extreme example of a low cardiac output 
state(35). 
In ischaemic hepatitis, Loosli et al, 1981, found rapid elevation of serum 
AT levels, with peak levels of 8 to 100 times the upper reference limit within 
24 hours. They fall rapidly if there is an improvement in the cardiac status, 
being less than twice normal within about six days. In ischaemic hepatitis 
serum bilirubin increases in most patients but rarely to more than four times 
normal. Alkaline phosphatase may increase up to twice normal. The 
prothombin time is not usually increased by more than two seconds. Serum 
albumin and  proteins are unaffected(12). Shovman  et al, in 1997, documented 
ischaemic hepatitis resulting from  acute hypoxia when low cardiac output 
further reduces oxygen supply, aggravating underlying congestion due to poor 
venous outflow.  He found elevated AT levels, elevated serum bilirubin level, 
prolonged prothrombin time and the presence of acute renal failure with 
reference to ischaemic hepatitis. He included ischaemic hepatitis should be 
considered whenever acute hepatitis follows a recent episode of systemic 
hypotension, especially in the context of concomitant congestive heart 
failure(36). 
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In 1981, Arcidi  et al, studied hepatic morphology in cardiac 
dysfunction. They have demonstrated chronic passive congestion and 
centrilobular necrosis potentiate the development of each other(37). These 
hepatic manifestations are considered  together since both are commonly seen 
at autopsy because there is an element of preterminal circulatory failure with 
virtually every death. Right sided cardiac failure leads to passive congestion of 
the liver. Left sided cardiac failure or shock leads to centribular necrosis. The 
combination of both produces centrolobular hemorrhagic necrosis known as 
nutmug liver(26).  
In most instances, the only clinical evidence of centrilobular necrosis or 
its variants is mild to moderate transient elevation of serum AT levels. The 
parenchymal damage may be sufficient  to induce mild to moderate 
jaundice(26).  
Ross et al, in 1981, revealed evidence of centrilobular necrosis and liver 
function derangements (38).  
Nanji et al, found mild to moderate increase in serum AT levels and 
accompanying  hyperbilirubinemia in 1983. They revealed marked increase in 
serm AT levels may occur rarely and usually preceded by prolonged shock or 
hypotensive episodes. The enzyme activities  get decreased sharply with 
improvement in  patients circulatory status(39).  
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Kubo et al, in 1987, after his  study on liver function abnormalities in 
chronic heart failure, concluded liver function abnormalities remain common in 
patients with congestive heart failure but are generally small in magnitude and 
not associated with clinically apparent hepatic disease. It is likely that reduced 
forward flow and passive backward congestion, together  are the contributing 
factors in the pathogenesis of these biochemical abnormalities(20). 
Mace et al, 1985, in their study of 65 infants and children with 
hemodynamic  abnormalities associated with congenital heart disease noted 
liver function derangements in most or all of the patients. When  patients 
hemodynamic status improved with treatment, the results of liver function tests 
returned towards normal(40).  
Arora et al, 1993, found a case of acute hepatic failure in constrictive 
pericarditis(41). 
Rober et al, 2002, in their study of cardiac hepatopathy with reference to 
clinical, hemodynamic, and histologic characteristics, found elevated  serum 
liver AT levels in cardiac dysfunction, particularly in acute cardiac failure. 
They grouped patients based on duration of cardiac dysfunction (42).  
Van Lingen  et al, 2005, studied jaundice as a presenting  feature of 
heart failure. They found jaundice due to heart disease tends to be mild. Both 
 16
passive congestion and ischaemic hepatits can produce jaundice though due to 
the former is more common(43). 
YEAR AUTHOR OBSERVATION 
1833 Kiernan et al Central liver necrosis in congestive heart failure 
1911 Mallory et al Central congestion with focal necrosis in congestive heart failure 
1943 Garvin et al Cirrhosis in heart disease patients 
1944 Koletsky et al Cirrhosis in heart disease patients 
1951 Sherlock S. et al Various anatomical, functional, biochemical changes of liver in heart failure 
1959 Bang et al Elevation of serum liver amiontransferases in heart failure 
1969 Killip et al Elevation of serum liver aminotransferases in cardiogenic shock 
1961 West et al Correlation of many cardiac factors and serum liver enzymes in heart failure 
1961 Richman et al 
Liver function test abnormalities in various 
forms of heart failure like acute, chronic,  left 
sided etc., 
1962  Logan et al 
Difference between serum enzyme elevation 
in heart failure and viral and drug induced 
hepatitis 
1963 Refsum et al Correlation between right sided heart failure and serum liver enzymes 
1969 Whelan et al Role of hypoxia in liver function test abnormalities 
1973 Dunn et al Liver function test abnormalities in congestive hepatopathy 
1979 Bynum et al Introduced the term “Ischaemic hepatitis” 
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YEAR AUTHOR OBSERVATION 
1980 Nouel et al Circulatory shock and fulminant hepatic failure 
1981 Loosli et al 
Alteration in liver serum enzymes, serum 
bilirubin, serum proteins and prothrombin 
time in ischaemic hepatitis 
1985 Mace et al Liver function derangements in congenital heart diseases 
1997 Shovman et al Hypotension and ischaemic hepatitis 
2002 Rober et al Clinical, hemodynaic, and histologic charac-teristics in cardiac hepatopathy 
2005 Van Lingen et al Jaundice as a presenting feature of heart failure 
2006 Ebert et al Massive elevation of liver serum enzymes in hypoxic liver injury. 
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CLINICAL COURSE AND MANAGEMENT 
NATURAL COURSE OF HEART FAILURE 
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          The outcome of patients with passive congestion of the liver relates to 
the underlying heart disease; rarely does liver disease cause significant 
morbidity or mortality in these patients. 
If heart failure can be controlled medically, the early histologic changes 
may resolve. However prolonged, persistent hepatic congestion may result in 
cardiac cirrhosis. This is classically seen in patients with either constrictive 
pericarditis or prolonged mitral valve disease and secondary tricuspid 
insufficiency. Neverthless, cardiac cirrhosis does not in itself confer a poor 
prognosis(3) . 
Ischaemic hepatitis is nearly always nonfatal and self-limited. The 
hepatic synthetic is usually impaired mildly, if at all; the prothrombin time is 
rarely prolonged by more than three seconds(3).  
The overall prognosis is related to the severity of the underlying heart 
disease, not the severity of the liver disease(12). Sherlock found no patients with 
cardiac cirrhosis showed stigmata of chronic liver disease or evidence of 
portosystemic shunting (8). Esophageal varies have not been documented as a 
result of cardiac cirrhosis alone. Even after progression to cardiac cirrhosis, 
control of heart failure can lead to a regression of histologic and clinical liver 
abnormalities, with only latent cirrhosis left(3) .            
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The cornerstone in the management of congestive hepatopathy is 
treatment of the underlying heart disease. Jaundice and hepatic congestion may 
respond dramatically to therapy with diuretics. Maintenance of adequate 
cardiac output is the paramount importance. Liver dysfunction reverts to 
normal after successful treatment(3). There is a dramatic fall in serum liver 
enzyme levels and serum bilirubin level after successful treatment of 
underlying heart failure. Solli et al, in 1992, and Squella et al, in 2003 found 
normalization of liver function tests in ischaemic hepatitis within five to ten 
days after the successful management of  the underlying heart disease. Kumada 
et al, in 1989, observed liver function tests come to normal within a few days if  
congestive cardiac failure is adequately managed. The elevated liver serum 
enzymes activities decrease sharply with improvement in the patients’ 
circulatory status (39) .  
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MATERIALS AND METHODS 
Setting 
Medical wards, Institute of Internal Medicine, Government General 
Hospital, Chennai 600003. 
Collaboration Department 
The Department of Biochemistry, Government General Hospital, 
Chennai 600003 and Liver clinic Department, Government General Hospital, 
Chennai 600003. 
Study Design  
Single centre, cross-sectional and analytical study. 
Period of Study 
January 2006 to September 2006. 
Consent 
Informed consent was obtained in all cases. 
Inclusion Criteria 
Congestive heart failure in all age groups. 
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Heart failure definition 
Heart failure is a clinical syndrome in which an abnormality of cardiac 
structure or function is responsible for the inability of the heart to eject or fill 
with blood at a rate commensurate with the requirements of the metabolizing 
tissues (53). 
Mechanisms of heart failure (54) 
1. Reduced ventricular contractility  
Eg. Myocardial infarction, cardiomyopathy. 
2. Ventricular outflow obstruction  
Eg. Rheumatic aortic stenosis. 
3. Ventricular inflow obstruction  
Eg. Rheumatic mitral stenosis. 
4. Ventricular volume overload  
Eg. Rheumatic mitral regurgitation and aortic regurgitation. 
5. Arrhythmia  
Eg. Atrial fibrillation. 
6. Diastolic dysfunction  
Eg. Constrictive pericarditis. 
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Forms of heart failure (53,54) 
1. Systolic heart failure  
Eg. Dilated cardiomyopathy. 
2. Diastolic heart failure 
Eg. Hypertensive heart disease, constrictive pericarditis and HOCM. 
3. Low output heart failure 
Eg. Dilated cardiomyopathy, hypertensive heart disease, Rheumatic 
mitral and aortic stenotic valvular diseases etc.., 
4. High output heart failure 
Eg. Anaemia and  Thyrotoxicosis. 
5. Right sided heart failure 
Eg. Cor pulmonale. 
6. Left sided heart failure 
Eg. Rheumatic mitral valvular diseases. 
7. Biventricular heart failure 
Eg. Coronary artery heart disease, dilated cardiomyopathy. 
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8. Acute heart failure 
Eg. Heart failure which develops suddenly as in myocardial function, 
compensated heart failure aggravated by precipitating factors like respiratory 
infection, arrhythmia etc.., 
9. Chronic heart failure 
Eg. Heart failure develops or progresses slowly as in Valvular heart 
diseases and dilated cardiomyopathies. 
Framingham criteria for diagnosis of congestive heart failure (53) 
Major Criteria 
1. Paroxymal nocturnal dyspnoea  
2. Neck vein distension  
3. Rales 
4. Cardiomegaly 
5. Acute pulmonary edema 
6. S3 gallop 
7. Increased venous pressure ( > 16 cmH2O ) 
8. Positive hepatojugular reflex 
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Minor Criteria 
1. Extremity edema 
2. Night cough 
3. Dyspnoea on exertion 
4. Hepatomegaly 
5. Pleural effusion  
6. Vital capacity reduced by one-third from normal 
7. Tachycardia ( > 120 bpm ) 
Major Or Minor  
Weight loss > 4.5 kg over 5 days’ treatment 
To establish a clinical diagnosis of congestive heart failure by these 
criteria, at least one major and two minor criteria are required.  
Exclusion Criteria 
1. History of alcoholism. 
2. Past history of jaundice. 
3. Recent intake of hepatotoxic and cholestatic drugs. 
4. Presence of HBs Antigen and Anti HCV Antibodies. 
5. Pregnancy. 
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6. Blood transfusion. 
7. Hemolytic disorders. 
8. Obstructive jaundice. 
9. Infectious hepatitis. 
Sample size 
Sixty patients with various aetiologies of heart failure. 
Selection of study materials 
Among cases admitted with heart failure in the medical wards, 
government general hospital, sixty patients who had met the inclusion and 
exclusion criteria were taken up for study. 
Selection of controls 
Among patients who attended medicine outpatient department, 
government general hospital, for general health check-up, twenty persons were 
taken up as controls. Controls and study group were matched according to the 
age and gender. They are excluded from diseases which are thought to 
influence the study by approprite investigations.   
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Details of the study 
After admission, complete history was elicited from all patients. After 
doing complete physical examination, clinical diagnosis of  congestive heart 
failure and the possible aetiology of heart failure was made. Patients who were 
found to have haemodynamic imbalance were adequately stabilized with 
appropriate management.  
After stabilization, they were subjected to complete investigations which 
included complete haemogram, plasma glucose, renal function tests, serum 
electrolytes, urine analysis, liver function tests, x-ray chest, ultrasonography of 
abdomen, electrocardiography and echocardiography etc..,  
Thyroid function tests and pulmonary function patients were done in 
selected patients. After completing all investigations the results were assessed 
for the study. 
All relevant investigations were done also in controls.   
Liver size is assessed by ultrasonagram. 
Liver function tests 
A large number of tests have been proposed, but many provide similar 
information.  
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The liver carries out thousands of biochemical functions, most of which 
cannot be easily measured by blood tests. Laboratory tests measure only a 
limited number of these functions. No one test enables the clinician to 
accurately assess the liver's total functional capacity. To increase both the 
sensitivity and specificity  of laboratory tests in the detection of liver disease, it 
is best to use them as a battery. Those tests usually employed in clinical 
practice are mentioned below. 
1. Tests used as indices of uptake, conjugation, and excretion of anionic 
compounds 
¡ Serum total bilirubin ( and direct and indirect ). 
2. Tests that reflect damage to hepatocytes 
¡ Serum aspartate and alaline aminotransferases. 
3. Tests that reflect cholestasis 
¡ Serum alkaline phosphatase. 
4. Tests that measure  biosynthetic functions of the liver 
¡ Serum proteins 
¡ Serum albumin.  
¡ Prothrombin time 
 29
Serum bilirubin  
      Bilirubin, a breakdown product of the porphyrin ring  of heme-
containing proteins, is found in the blood in two fractions-  a water soluble, 
conjugated, direct fraction and a lipid soluble, unconjugated, indirect fraction. 
In our laboratory specific agents are used to detect the quantity of bilirubin in 
the serum.             
                         Reagent                  Amount            Sample           Amount                                
Total          Total bilirubin               1000              Serum     50 microlitres    
bilirubin     Reagent                       microliters                     
                   & Sodium nitrite    25 microlitres   
 
Direct  Direct bilirubin              1000               Serum         50 microlitres           
bilirubin     Direct   Reagent       microlitres                                                         
                  & Sodium nitrite    25 microlitres                                                                           
Indirect bilirubin = ( Total bilirubin – Direct bilirubin ) 
METHOD : Erba semi autoanalyzer after ten minutes incubation. 
Serum enzyme assays 
The aminotransferases participate in gluconeogenesis by catalyzing the 
transfer of amino groups from aspartic acid or alanine to ketoglutaric acid to 
produce oxaloacetic acid and pyruvic acid, respectively. SGPT  is a cytosolic 
enzyme, whereas SGOT is present as both cytosolic and mitochondrial 
enzymes. Elevation of the activity of these enzymes in serum is believed to be 
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the result of leakage from damaged cells and thus reflects hepatocyte injury. 
Hence, Serum liver aminotransferases are sensitive indicators of liver cell 
injury and most useful in recognising acute hepatocellular diseases.  Alanine 
aminotransferase is found primarily in the liver whereas aspartate 
aminotransferase is found in many organ systems. The aminotransferases are 
normally present in the serum in low concentrations.  
These enzymes are released into the blood in greater amounts when 
there is damage to the liver cell membrane resulting in increased permeability. 
However, there is a poor correlation between the degree of liver damage and 
the level of aminotransferases. Striking elevations occur with extensive 
hepatocellular injury as ischaemic hepatitis. 
                     Reagent              Amount   Sample       Amount            
SGOT    OT reagent        500 microlitres     Serum     50 microlitres 
SGPT PT enzyme reagent    400 microlitres      Serum          50 microlitres                               
   & Starter reagent       100 microlitres 
METHOD : Erba semi autoanalyzer.                                                                                             
The alkaline phosphatase is found in or near the bile canalicular 
membrane of hepatocytes. It is usually elevated in cholestasis. The normal  
serum alkaline phosphatase consists of many distinct isoenzymes found in 
various organs. Elevation of liver-derived alkaline phosphatase is not totally 
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specific for cholestasis and a less than threefold elevation can be seen in almost 
any type of liver disease. Isolated elevations of alkaline phosphatase can  occur 
in congestive heart failure. 
Reagent      Amount  Sample       Amount 
SAP     SAP reagent    500 microlitres        Serum           15 microlitres       
METHOD : Erba semi autoanalyzer. 
Serum proteins 
The liver makes many circulating plasma proteins. Not surprisingly liver 
disease affects the plasma concentration of many of them. However the effects 
are complex and depend not only on changes in protein synthesis, but also on 
the effects of liver disease on the volume and distribution of  extracellular 
fluids, on the half life of individuals proteins, on their catabolism by various 
tissues. There may also be changes in the metabolism of plasma proteins 
produced outside the liver.  It is often normal when there are gross disturbances 
of individual components.  
When the total level is either high or low its significance can only be 
interpreted by measurement of the major fractions. Measurement of total 
protein together with albumin is used to calculate globulin fraction by 
difference.  
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Reagent Amount   Sample    Amount                   
Serum     Serum protein   1000 microlitres         Serum            10 microlitres 
Proteins   reagent 
METHOD : Erba semi autoanalyzer. 
Serum albumin 
Albumin is the most abundant circulating protein. Liver is the only site 
of synthesis. When synthesis is reduced, the drop in plasma albumin is 
minimized by a reduction in its fractional catabolic rate. The serum albumin is 
widely regarded as a test of liver function, as if reflects hepatic protein 
synthesis. Low values can result from increased gastrointestinal or renal loss, 
increased catobolism, altered vascular permeability, or overhydration. 
Furthermore it may take many days before reduced synthesis causes an obvious 
change in serum albumin because it has a long half-life ( about 20 days ). 
Hence, serum albumin concentration should be interpreted with caution. 
Reagent  Amount    Sample      Amount   
Serum       Serum albumin       1000 microlitres      Serum   10 microlitres     
albumin      reagent      
 METHOD : Erba semi autoanalyzer.   
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Serum prothrombin time 
With the exception of factor VIII, the blood clotting factors are made 
exclusively in hepatocytes. Their serum half-lives are much shorter than 
albumin, ranging from six hours for factor VII fo five days for fibrinogen. 
Serum prothrombin time collectively measures factors II, V, VII, and X. 
Biosynthesis of these factors depends on vitamin K. 
Reagent  Amount Sample  Amount  
 PT         PT  Reagent    200 microlitres   venous blood        100 microliters 
PT reagent contains lyothilized human placental thromboplastin, CaCl2  
and preservatives. 
METHOD : Autoanalyzer. 
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RESULTS 
GENDER DISTRIBUTION IN HEART FAILURE 
 
SEX NO. OF CASES 
MALE 36 
FEMALE 24 
TOTAL 60 
MALE AND FEMALE RATIO = 1.5 : 1 
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AGE GROUP DISTRIBUTION IN HEART FAILURE 
 
AGE GROUP NO. OF. CASES 
<40 YRS 13 
40-50 YRS 20 
50-60 YRS 17 
>60 YRS 10 
TOTAL 60 
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AETIOLOGY OF HEART FAILURE 
 
 
DIAGNOSIS MALE FEMALE TOTAL PERCENTAGE
RHD 13 11 24 40% 
DCM 8 6 14 23.3% 
CAHD 7 1 8 13.3% 
COR PULMONALE 3 2 5 8.3% 
OTHERS 5 4 9 15% 
TOTAL 36 24 60 100% 
 
 
 
 
AETIOLOGY OF HEART FAILURE
13
8 7
3
5
11
6
1
2
4
0 
5 
10
15
20
25
30
RHD DCM CAHD COR PULMONALE OTHERS
DIAGNOSIS
N 
O
 
O
F 
C 
A 
S 
E 
S 
MALE FEMALE
 37
DURATION OF HEART FAILURE 
 
DURATION GENDER 
ACUTE CHRONIC 
MALE 2 34 
FEMALE 3 21 
TOTAL 5 55 
 
 
PERCENTAGE OF JAUNDICE 
GENDER TOTAL NO. OF 
CASES 
NO. OF CASES WITH 
JAUNDICE 
MALE 36 7 
FEMALE 24 5 
TOTAL 60 12 
 
PERCENTAGE OF JAUNDICE = 20% 
PERCENTAGE OF HEPATOMEGALY 
 
GENDER TOTAL NO. OF 
CASES 
NO. OF CASES WITH 
HEPATOMEGALY 
MALE 36 22 
FEMALE 24 16 
TOTAL 60 38 
 
PERCENTAGE OF HEPATOMEGALY = 63% 
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PERCENTAGE OF HYPERBILIRUBINEMIA 
GENDER TOTAL NO. OF 
CASES 
NO. OF CASES WITH 
HYPERBILIRUBINEMIA
MALE 36 26 
FEMALE 24 20 
TOTAL 60 46 
 
PERCENTAGE OF HYPERBILIRUBINEMIA = 77% 
PERCENTAGE OF HYPERBILIRUBINEMIA 
 
 
PERCENTAGE OF HYPERBILIRUBINEMIA
77%
23%
HYPERBILIRUBINEMIA NORMAL
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PERCENTAGE OF ELEVATED SERUM AMINOTRANSFERASES 
TOTAL NO. OF CASES 60 
NO. OF CASES WITH ELEVATED AMINOTRANSFERASES 47 
PERCENTAGE OF ELEVATED AMINOTRANSFERASES = 78% 
PERCENTAGE OF ELEVATED SERUM ALKALINE PHOSPHATASE 
TOTAL NO. OF CASES 60 
NO. OF CASES WITH ELEVATED SERUM ALKALINE 
PHOSPHATASE 
15 
PERCENTAGE OF ELEVATED ALKALINE PHOSPHATASE = 25% 
PERCENTAGE OF LOW SERUM PROTEINS 
TOTAL NO. OF CASES 60 
NO. OF CASES WITH LOW SERUM PROTEINS 43 
PERCENTAGE OF LOW PROTEINS = 72% 
PERCENTAGE OF LOW SERUM ALBUMIN 
TOTAL NO. OF CASES 60 
NO. OF CASES WITH LOW ALBUMIN 56 
PERCENTAGE OF LOW ALBUMIN= 93% 
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PERCENTAGE OF PROLONGED PROTHROMBIN TIME 
TOTAL NO. OF CASES 60 
NO. OF CASES WITH PROLONGED PROTHROMBIN TIME 53 
PERCENTAGE OF PROLONGED PROTHROMBIN TIME = 88% 
GROUP 
STUDY 
GROUP 
CONTROL 
GROUP S. NO. VARIABLES 
MEAN SD MEAN SD 
P VALUE 
 
1. EF (%) 51.10 7.83 61.44 4.00 <0.01** 
2. Liver Size (cm) 14.53 2.51 12.84 1.43 0.002** 
3. Total Serum Bilirubin (mg/dl) 1.81 1.16 0.88 0.08 <0.01** 
4. Conjugated Bilirubin (mg/dl) 0.18 1.17 0.05 0.06 <0.01** 
5. Unconjugated Bilirubin (mg/dl) 1.63 1.01 0.83 0.07 <0.01** 
6. SGOT (U/l) 113.55 77.68 42.44 21.67 <0.01** 
7. SGPT (U/l) 99.92 64.97 37.48 19.36 <0.01** 
8. SAP (U/l)  128.12 56.34 126.8 52.2 0.920 
9. Serum Protein (g/dl) 6.55 0.53 6.94 0.67 <0.005** 
10. Serum Albumin (g/dl) 3.27 0.56 4.04 0.35 <0.01** 
11. A/G Ratio  1.02 0.26 1.43 0.27 <0.01** 
12. Prothrombin time (sec.) 14.55 4.07 11.24 0.44 <0.01** 
Note :  
**P Value ≤ 0.01 = Significant at 1% level 
*P Value  0.011 to 0.05  = Significant at 5% level 
P Value >0.05 =  Not Significant at 5% level 
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RANGE 
 
S. NO. VARIABLES RANGE 
1. Liver Size 11 cm to 20 cm 
2. Total Serum Bilirubin 0.6 mg/dl to 5.2 mg/dl 
3. Serum Albumin 2.2 g/dl to 4.3 g/dl 
4. SGOT 16 U/l to 334 U/l 
5. SGPT 18 U/l to 360 U/l 
6. SAP 45 U/l to 310 U/l 
 
CORRELATION COEFFICIENTS 
 LIVER 
SIZE 
TOTAL 
BILIRUBIN 
CONJ.  
BILIRUBIN 
UNCONJ. 
BILIRUBIN 
Liver Size - 
r=0.57 
p=<0.01 
r=0.40 
p=<0.02 
r=0.58 
p=<0.01 
Total 
Bilirubin 
r=0.57 
p=<0.01 
- 
r=0.86 
p=<0.01 
r=1 
p=<0.01 
Conj. 
Bilirubin 
r=0.40 
p=<0.02 
r=0.86 
p=<0.02 
- 
r=0.81 
p=<0.01 
Unconj. 
Bilirubin 
r=0.58 
p=<0.01 
r=1 
p=<0.01 
r=0.81 
p=<0.01 
- 
 
Note :  
 ‘r’ indicates correlation (eg. r value of 0.57 denotes 57%  correlation) 
 ‘p’ indicates significance (p value <0.01 indicates significance at 1% level) 
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t- test for 
SGOT  to  SGPT RATIO 
VARIABLE NO. OF. CASES MEAN SD P VALUE 
STUDY GROUP 60 1.1974 0.476 
CONTROL GROUP 25 1.1952 0.369 
0.984 
 
Table values indicate SGOT to SGPT ratio is almost similar in both groups. 
t-test for SGOT and SGPT 
VARIABLE r value p value 
SGOT 
SGPT 
0.92 <0.01 
 
Table values suggest a strong correlation between SGPT and SGOT 
which is considered to be significant at 1% level (p=<0.01) 
SGOT VS UNCONJUGATED BILIRUBIN 
SGOT 
 
≤ 42 > 42 
P VALUE 
≤ 0.83 50% 50% 
Unconj. Bilirubin > 0.83 13% 87% 0.003 
 Values indicate a significant correlation between SGOT and 
unconjugated bilirubin 
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DURATION 
ACUTE CHRONIC  
S.NO. 
 
VARIABLES 
MEAN SD MEAN SD 
 
P VALUE 
1. Total Bilirubin 3.18 1.05 1.68 1.09 0.005 
2. SGOT 200.4 91.45 105.65 72.19 0.008 
3. SGPT 172.2 63.28 93.35 61.55 0.008 
4. Serum Albumin 3.46 0.42 3.25 0.57 0.433 
Note : 
p value <0.01 indicates significance at 1% level 
p value > 0.05 indicates not significant at 5% level 
 
HYPOTENSION 
PRESENT NORMAL BP  
S.NO. 
 
VARIABLES 
MEAN SD MEAN SD 
 
P VALUE 
1. Total Bilirubin 3.93 1.14 1.69 1.06 0.001 
2. SGOT 239.33 54.12 106.93 73.21 0.003 
3. SGPT 173.33 4.16 96.05 64.37 0.044 
Note: 
p value <0.01 indicates significance at 1% level 
p value 0.011 to 0.05 indicates significance at 5% level 
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DISCUSSION 
To characterize the incidence and severity of  liver function 
abnormalities in patients with heart failure, the present study analyzed liver 
biochemical profiles in sixty cases with heart failure of varied aetiologies and 
mechanisms. Innumerable references about the clinical and biochemical 
parameters  about the hepatic circulation, hepatic function and the over all 
disturbance in the liver function secondary to heart failure of varied aetiologies 
have been correlated with the present study of sixty cases. Sincere effort has 
been made to correlate the results. 
JAUNDICE 
Clinical jaundice was present in 12 cases among total sixty cases.  
Present study showed 20% cases with jaundice in heart failure patients. We 
have found no correlation between the presence of jaundice and the duration of  
heart failure. Whereas heart failure patients with hypotensive episodes showed 
a strong correlation with clinical jaundice.  
Jaundice was present in all three cases of heart failure with low blood 
pressure.  
Dunn et al, in their study on the liver in congestive heart failure, 
observed 20%  cases with jaundice(17). White et al, observed jaundice in 21% of  
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their cases(25). Van Lingen et al, observed only eight (1.2%) cases with jaundice 
in their retrospective study on jaundice as a presentation of heart failure in 661 
cases. All eight patients had severe cardiac dysfunction. He found jaundice due 
to heart disease tends to be mild and the most common mechanism is hepatic 
passive congestion (47).  Richman et al, found jaundice in 5% cases(19).  
Sherlock et al, in their study of 50 patients with heart failure, found eight 
cases with jaundice. She concluded jaundice in right heart failure results from 
congestion and greater the extent of zone 3 necrosis the deeper the jaundice(8).  
             AUTHOR                     PERCENTAGE OF JAUNDICE 
            Dunn et al                                           20% 
           White et al                                           21% 
           Van Lingen et al                                   1.2%    
           Richman et al                                       5% 
           Sherlock et al                                       16% 
           Present study                                       20% 
HEPATOMEGALY 
Liver size more than 13 cm by ultrasonography is defined as 
hepatomegaly in our study. Enlarged liver  is seen in 63% of cases which is 
considered to be highly significant (P = 0.002) in heart failure patients. 
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Maximum size of the liver goes up to 20 cm which is seen in three patients. 
Present study revealed a significant  (P = < 0.01) correlation between increase 
in liver size and increase in both total (r = 0.57) and unconjugated (r = 0.58) 
serum bilirubin levels. Whereas there is no significant correlation between 
hepatomegaly and conjugated serum bilirubin levels. Dunn et al, found 95% of  
hepatomegaly in congestive heart failure patients(17). White et al, observed 95 
to 99% cases with hepatomegaly. Jurg Reichen et al, observed hepatomegaly in 
95 to 99% of patients in right sided heart failure (20). 
        AUTHOR                             PERCENTAGE OF HEPATOMEGALY 
         Dunn et al                                                95% 
        White et al                                                95-99% 
         Jurg Reichen et al                                     95-99%   
         Present study                                           63%   
HYPERBILIRUBINEMIA  
Total serum bilirubin level more than 0.9 mg/dl is taken as 
hyperbilirubinemia according to our study. Serum hyperbilirubinemia is seen in 
77% of  heart failure patients in the present study which is considered as highly 
significant ( P = < 0.01 ) in comparison with control cases. The maximum level 
goes up to 5.2 mg/dl, which is seen in two patients.  
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The present study revealed a significant (P = < 0.01) correlation (r = 1) 
between the total and the unconjugated fraction. Unconjugated fraction values 
were found to be higher than the conjugated fraction. Dunn et al, observed mild 
elevation of the serum bilirubin in 70% of congestive heart failure patients. He 
found the total serum bilirubin is usually less than 3 mg/dl, with a high 
unconjugated fraction(17). Kubo et al, found hyperbilirubinemia within the value 
of  2.5 mg/dl(20). Sherlock found the serum bilirubin level usually exceeds 1 
mg/dl and in about one-third it is more than 2 mg/dl(8).  
         AUTHOR                  PERCENTAGE OF HYPERBILIRUBINEMIA 
        Sherlock et al                                                   68% 
        Felder et al                                                       52% 
        Evans et al                                                       26%      
        White et al                                                       40%  
        Dunn et al                                                        70% 
        Present study                                                   77%        
Present study shows total serum bilirubin level is higher in acute heart 
failure than in chronic heart failure. There is significant (P = 0.005) correlation 
between elevated total serum bilirubin and acute heart failure when compared 
to chronic heart failure.  
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Richman et al, described liver function abnormalities in 175 patients 
with congestive heart failure. They found acute heart failure is associated with 
more elevation of  total serum bilirubin(19). 
Present study found an unusually high total serum bilirubin level in 
patients presented with hypotension. A significant (P = 0.001) correlation was 
found in those cases. Bilirubin levels are higher even than in acute heart failure. 
Shovman et al, described ischaemic hepatitis in congestive heart failure after an 
episode of  hypotenion. 
They found a rise in serum bilirubin in their study. They finally 
concluded ischaemic hepatitis should be considered whenever  acute hepatitis 
follows a recent episode of hypotension (40).  
Virtually any cause of shock or hemodynamic instability can result in 
ischaemic injury to the liver(3). The main mechanism proposed for the 
development of  centrilobular necrosis is a severe decrease in cardiac output, 
the resulting hepatic hypoxia causing damage to the hepatocytes(9). The serum 
total bilirubin level rises above four times the upper limit of normal in 
ischaemic hepatitis(3).  
Present study  revealed more than threefold rise in serum bilirubin level 
in patients with hypotension. Gibson et al, observed abnormal liver function 
tests due to ischaemic hepatitis secondary to acute illness associated with a fall 
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in cardiac output and systemic hypotension, characterized by marked increase 
in serum bilirubin(12).    
SERUM AMINOTRANSFERASES 
SGOT level of  more than 42 U/l and SGPT level of  more than 37 U/l 
are taken as elevated levels according to our study. Present study revealed 78% 
cases with elevated liver serum aminotransferasesin sixty heart failure patients 
which is considered as highly significant (P = < 0.01).  
 Maximum serum level goes up to 360 U/l in SGOT and up to 334 in 
SGPT. Present study reveals a significant (P = < 0.01) correlation between 
elevation of  SGOT and SGPT in heart failure patients. Again a significant  
(P = 0.003) correlation was identified between elevation of SGOT and 
elevation of  unconjugated bilirubin levels. Preseny study found SGOT levels 
are higher than SGPT levels.  
 Richman et al, found though both aminotransferases were high in his 
study on alterations in liver function in congestive heart failure with particular 
reference to serum enzymes, SGPT levels were less marked than, those of  
SGOT levels.  
 The serum AT levels are only mildly elevated in congestive heart 
failure, usually to two to three times normal levels(3). Kubo et al, found 
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significantly higher levels of  AT levels in severe heart failure patients(20). 
Nanji et al, observed high SGOT values in congestive heart failure patients. 
They observed congestive heart failure usually features a mild to moderate 
increase in SGOT level. A marked increase in SGOT level may occur rarely(43).  
 In the present study, ratio between SGOT and SGPT  was found to be 
not significant in comparison with control cases (P = 0.984). Whereas there is a 
significant (P = < 0.01) correlation (r = 0.92)  between elevation of SGOT and 
SGPT levels in the study group.  
 Duration of heart failure affects serum levels of aminotransferases. 
Present study observed serum aminotransferases' levels are higher in acute 
heart failure than in chronic heart failure which is highly significant (P=0.008). 
Study reveals threefold to eightfold rise in aminotransferases' level in acute 
heart failure. Heart failure patients with hypotension were found to have a 
massive elevation of aminotransferases levels.  
 In a series of 175 patients with acute and chronic heart failure, Richman 
et al, observed higher SGOT levels in acute heart failure than chronic heart 
failure(19). 
 Sherlock et al, found very high values of  SGOT can occur with an acute 
onset of severe heart failure, especially if it is associated with hypotension or 
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shock(8). However, high serum aminotransferaes levels have been described in 
the setting of heart failure with minimal or no hemodynamic instability(9). 
 Increased venous congestion and decreased hepatic perfusion  both 
contribute to the elevation of  aminotransferases, although centrilobular 
hypoxia and/or necrosis are probably the major factors(48). Henrion et al, 
studied 142 cases of hypoxic hepatitis. He found in congestive heart failure and 
acute heart failure, the hypoxia of the liver resulted from decreased hepatic 
blood flow (ischaemia) due to left sided heart failure and from venous 
congestion secondary to right sided heart failure. In chronic respiratory failure, 
liver hypoxia was mainly due to profound hypoxemia. A shock state was 
observed in only about 50% of cases(51).  
 Present study revealed the ratio of  SGOT  to SGPT  is 1.2 (mean) in 
both study and control groups which is considered to be not significant  
(P = 0.984). It excludes the presence of  alcoholic hepatitis since this ratio is 
characteristically greater than two in such cases(49).  
SERUM ALKALINE PHOSPHATASE 
 Serum alkaline phosphatase level more than 127 U/l  is taken as higher 
than normal according to our study. Present study observed elevation of serum 
alkaline phosphatase in 15 cases (25%) among 60 heart failure cases which is 
considered to be not significant (P = 0.920). Maximum level goes up to 310 U/l 
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which is seen in one patient. In most of the cases the level is less than twofold 
rise.                  
 Kubo et al and Sherlock et al, found rise in serum alkaline phosphatase  
by about 10 to 20%  cases with congestive heart failure (8,20). Richman et al, 
found intrahepatic biliary obstruction due to a high intrahepatic pressure may 
play a role in the alkaline phosphatase rise with congestive heart failure(19).  
SERUM PROTEINS AND SERUM ALBUMIN 
 The estimation of total plasma protein alone is of  relatively little value. 
It is often normal even when there are gross differences of individual 
components. When the total level is either high or low its significance can only 
be interpreted by measurement of the major fractions (48).            
 Present study has taken serum level less than 6.9 g/dl as evidence for 
decreased serum proteins level and serum level less than 4.0 g/dl as evidence 
for hypoalbuminemia. Low serum proteins level was found in 72% of cases 
and low albumin values were found in 93% of cases with sixty heart failure 
patients which are considered to be highly significant (P = < 0.01). The ratio of  
serum albumin to globulin below 1.43 is considered evidence for low A/G ratio 
according to the present study. Present study observed low A/G ratio in 93% of 
cases which is highly significant (P = < 0.01). Felder  et al, found decresed  
serum albumin level in 26% of cases(24). Naresh et al, found low serum albumin 
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level in 39% of cases with congestive heart failure. Richman et al, found low 
serum albumin in 30 to 50%  of patients with congestive heart failure. He 
observed the incidence, and degree of change appears to be similar in acute and 
chronic heart failure(19). Present study also revealed there is no significance  
(P = 0.433) in serum albumin level with acute heart failure when compared to 
chronic heart failure.                                           
 The serum albumin level does not correlate with the degree of 
histological damage to the liver(19,24). Present study revealed extremely low 
serum albumin in most of the patients. Changes in serum albumin 
concentration should be interpreted with caution because many conditions 
other than liver disease are associated with low albumin levels.  
 This low albumin value could be attributed to many factors which 
includes increased gastrointestinal or renal loss, reduced dietary intake of 
protein as a result of decreased appetite, increased catabolism, leakage from a 
congested intestine and overhydration.  
 Thus a low serum albumin level is not specific for liver disease.  
 SERUM PROTHROMBIN TIME 
Serum prothrombin time is often prolonged in congestive heart 
failure(17,19,25).  Present study found prolonged prothrombin time in 88% of 
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cases with sixty heart failure patients which is considered highly significant  
(P = < 0.01). PT  more than 11 seconds is taken as abnormal value according to 
the study. White et al, found prolonged PT  in 80 to 90% of  cases with acute 
and chronic heart failure(25). Present study observed there is only a mild 
elevation in prothrombin time. Caution should therefore be exercised when 
treating patients in heart failure with oral anticoagulants. 
 55
SUMMARY 
 
            Abnormal liver  enzymes and liver function in congestive cardiac 
failure has long been recognized and occurs quite frequently in acute and 
chronic failure(19). The present  study was undertaken to identify  alterations in 
the liver biochemical profiles in relation  to congestive heart failure and also to 
show their significance with respect to the duration  of heart failure. 
            Sixty cases with heart failure of various aetiologies and twenty healthy 
controls  were included in the study. In the present study, number of male cases 
were higher than number of female  cases. Among sixty total cases 36 male and 
24 female cases were present. Higher number of cases were found within the 
age group of 40 to 50 years followed by the age group of  50 to 60 years. 
         The present study revealed rheumatic heart disease is still the leading 
cause of heart failure in our set up. Among the total heart failure cases, 40%  
were due to rheumatic heart disease. Dilated cardiomyopathies represent about 
23% of cases. Heart failure  secondary to coronary artery heart disease is seen 
in about 13% of cases. We have found five cases with acute heart failure and 
three cases with hypotension.  
Present study revealed a strong correlation between liver function 
derangements and the above cases. 
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          Serum bilirubin, serum aminotransferases, serum alkaline phosphatase, 
serum proteins, serum albumin and prothrombin time were the liver 
biochemical tests used in the study. Echocardiography and ultrasonography of 
the liver were also done in all cases. 
          Present study has found a strong relationship between liver function 
derangements and heart failure cases. The study observed 20%  of cases with 
jaundice. Among sixty cases liver enlargement was seen in 63%  of cases. 
Increased liver size is strongly correlated with hyperbilirubinemia. Though the 
conjugated fraction of bilirubin is also elevated, the levels of unconjugated 
fraction were higher.  
Serum aminotransferases were elevated in 78% of cases unlike serum 
alkaline phosphatase which is increased only in 25% of cases. There found to 
be a significant correlation between rise in unconjugated bilirubin and elevation 
of serum aminotransferases. Study revealed marked alterations in liver function 
with acute heart failure and during hypotension when compared to chronic 
heart failure.  
Low serum proteins and serum albumin levels are seen in many of  the 
cases. Various factors play in causing these changes which have already been 
discussed. Serum prothrombin time, though prolonged in 88% of cases, the 
changes were only mild. 
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CONCLUSION 
 
         The present study undertaken shows a significant changes in liver 
biochemical profiles in patients with congestive heart failure. These changes 
are found to be useful in assessing the duration and severity of heart failure.   
          The liver performs a diverse array of biochemical, synthetic, and 
excretory functions, and as a result, no single biochemical test is capable of  
providing an accurate global assessment of hepatic function. Hence, clinical 
evaluation, a complete biochemical profile, the underlying cause and radiologic 
imaging are necessary to interpret the liver function tests.     
         The altered liver functions in heart failure patients are often reversible. 
The present study suggests an early detection of  liver function abnormalities in 
heart failure patients. Treatment should mainly be focused on the underlying 
heart disease. Regression in liver derangements occurs after successful 
treatment of heart failure in most of the cases.  
Present study could not follow up all sixty cases to assess the regression 
of liver function abnormalities due to practical concerns. 
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         Maintenance of  stable hemodynamic status is of paramount importance. 
Even in ischaemic hepatitis, the liver is able to regenerate and recover normal 
function if  appropriate treatment is applied to the underlying heart disease.  
          Care must be taken to avoid excessive diuresis in patients with severly 
impaired cardiac output, which  can impair hepatic perfusion and precipitate 
zone 3 necrosis. Since many of our patients showed prolonged serum 
prothrombin time, cautious use of oral anticoagulants is advised in those cases. 
           So, present study concluded early identification of  changes in liver 
biochemical profiles  is not only useful in assessing the duration and severity of 
heart failure but also  in preventing permanent hepatic damage.           
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ABBREVIATIONS 
AT  - Aminotransferase 
HBs Ag - Hepatitis B surface antigen 
Anti HCV Abs -Anti hepatitis C virus antibodies  
SGOT - Serum glutamic oxaloacetic transaminase  
SGPT – Serum glutamic pyruvic transaminase 
PT – Prothrombin time 
SAP – Serum alkaline phosphatase  
CaCl2  - Calcium chloride 
A/G ratio – Albumin globulin ratio 
 PROFORMA 
Name 
Age 
Sex 
MRD No. 
PRESENTING COMPLAINTS                                       DURATION 
Chest pain  
Breathlessness 
Palpitations 
Syncope 
Cough  
Haemoptysis 
Swelling of legs 
Oliguria 
Fever 
Other symptoms 
PAST HISTORY                                                                  DURATION 
Similar illness in the past 
Diabetes mellitus 
Hypertension 
Coronary artery heart disease 
Bronchial asthma 
Jaundice 
 Rheumatic fever 
Pulmonary tuberculosis 
Transient ischaemic attacks 
Abortion / Exposure to sexually transmitted diseases 
PERSONAL HISTORY 
Smoking 
Alcoholism 
FAMILY HISTORY 
Hypertension 
Diabetes mellitus 
Coronary artery heart disease 
CLINICAL EXAMINATION 
Consciousness 
Orientation 
Temperature 
Anaemia 
Jaundice 
Cyanosis 
Clubbing 
Pedal edema 
Lymph node enlargement 
Jugular venous pressure 
Signs of infective endocarditis 
Signs of liver failure 
 Pulse 
Blood pressure 
Respiratory rate 
CARDIOVASCULAR SYSTEM 
Parasternal heave 
Abnormal pulsations 
Heart sounds and murmurs 
RESPIRATORY SYSTEM 
Respiratory rate 
Breath sounds 
Added sounds 
ABDOMEN 
Appearance 
Ascites  
Hepatomegaly 
Spleenomegaly 
CENTRAL NERVOUS SYSTEM 
Higher functions 
Cranial nerves 
Spinomotor system 
Sensory system 
Cerebellar system 
Spine and cranium 
 DIAGNOSIS 
INVESTIGATIONS 
Blood hemogram 
Urine routine 
Blood sugar 
Blood urea and serum creatinine 
Serum electrolytes 
HBs Ag 
Anti HCV Abs 
Electrocardiography 
Echocardiography 
Chest x ray 
Liver function tests - Serum bilirubin Total 
                                                                 Direct 
                                                                  Indirect 
                                   SGOT 
                                   SGPT 
                                   SAP 
                                   Serum proteins 
                                   Serum albumin 
                                   A/G ratio 
Prothrombin time 
Ultrasonography of abdomen 
